UK markets closed

Halozyme Therapeutics, Inc. (0J2O.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
38.62+0.24 (+0.64%)
At close: 03:51PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 315.67%
S&P500 52-week change 322.36%
52-week high 344.71
52-week low 330.09
50-day moving average 336.88
200-day moving average 337.43

Share statistics

Avg vol (3-month) 31.67k
Avg vol (10-day) 3452
Shares outstanding 5143.95M
Implied shares outstanding 6N/A
Float 8125.47M
% held by insiders 11.08%
% held by institutions 1100.29%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 33.96%
Operating margin (ttm)45.01%

Management effectiveness

Return on assets (ttm)11.89%
Return on equity (ttm)222.07%

Income statement

Revenue (ttm)829.25M
Revenue per share (ttm)6.29
Quarterly revenue growth (yoy)26.70%
Gross profit (ttm)N/A
EBITDA 416.93M
Net income avi to common (ttm)281.59M
Diluted EPS (ttm)3.00
Quarterly earnings growth (yoy)48.00%

Balance sheet

Total cash (mrq)336M
Total cash per share (mrq)2.65
Total debt (mrq)1.53B
Total debt/equity (mrq)1,827.33%
Current ratio (mrq)6.64
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)388.57M
Levered free cash flow (ttm)268.16M